Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8862408 | 0.85 | TSHR (0.57) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL431806 | 0.78 | TSHR (0.60) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL17826781 | 0.77 | TSHR (0.48) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL282472 | 0.77 | TSHR (0.67) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL10040020 | 0.75 | TSHR (0.57) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL9654507 | 0.75 | TSHR (0.63) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL4060148 | 0.71 | TSHR (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL14902971 | 0.71 | TSHR (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL5664086 | 0.71 | TSHR (0.41) | TSHRPPARDMEN1KMT2A | |
| Dimethylamine SCHEMBL27510386 | 0.70 | TSHR (0.57) | TSHRTP53TDP1PPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132427-B2 | Quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1463742-A4 | NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1412367-A4 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7019139-B2 | Quinolinones and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1408985-A4 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-7009054-B2 | Quinolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| EP-1408971-A4 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6960572-B2 | Indolinones and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1408978-A4 | NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6878697-B2 | Phenylamino-pyrimidines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | ARIAD PHARMACEUTICALS,INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030100573-A1 | Novel quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000266-A1 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000270-A1 | NOVEL PYRIDOPYRIMIDONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000186-A2 | NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000251-A1 | NOVEL IDOLINONES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000011-A2 | NOVEL PYRIDOPYRIMIDINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000188-A2 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000187-A2 | NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000705-A1 | NOVEL QUINOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100572-A1 | Novel pyridopyrimidones and uses thereof | UQCRB, RRM2B, CYP2B6 | TSHR 1337/4885TP53 2808/4885TDP1 1092/4885 |
| US-20030100573-A1 | Novel quinazolines and uses thereof | UQCRB, NQO2, RAB7A | TSHR 2143/4885TP53 3572/4885TDP1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.